The Next Ultimate Growth Stock: "That's our tack at Rule Breakers. Thus far, our picks are beating the market since our launch in October 2004. Exelixis, a biotech with promising cancer drugs in its pipeline, has returned 43% since we first recommended it in November 2005. Exelixis has drug partnerships with powerhouses such as GlaxoSmithKline (NYSE: GSK), and the Rule Breakers team believes it has the potential to become the next Genentech."
Posted by <> at 16:59